Technical Analysis for CTSO - Cytosorbents Corporation

Grade Last Price % Change Price Change
grade F 5.53 0.55% 0.03
CTSO closed up 0.55 percent on Friday, September 20, 2019, on 78 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CTSO trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
MACD Bullish Centerline Cross Bullish 0.55%
1,2,3 Pullback Bullish Bullish Swing Setup 0.55%
Narrow Range Bar Range Contraction 0.55%
NR7 Range Contraction 0.55%
NR7-2 Range Contraction 0.55%
NR7 Range Contraction 2.60%
Upper Bollinger Band Walk Strength 2.60%
Wide Bands Range Expansion 2.60%
Overbought Stochastic Strength 2.60%

Older signals for CTSO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
CytoSorbents Corporation, a development stage company, is engaged in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company develops its adsorbent polymer technology for various applications in the medical field, primarily to provide blood purification for acute and chronic health complications associated with blood toxicity. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications, including acute respiratory distress syndrome, severe burn injury, trauma, and pancreatitis; to prevent and treat organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and for the prevention and treatment of post-operative complications of cardiopulmonary bypass surgery. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Medicine Medical Specialties Clinical Medicine Disease Imaging Medical Equipment Membrane Technology Injury Renal Dialysis Transfusion Medicine Kidney Disease Blood Products Sepsis Adjunctive Therapy Care Applications Toxic Chemicals
Is CTSO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 13.95
52 Week Low 3.68
Average Volume 187,834
200-Day Moving Average 7.0103
50-Day Moving Average 5.7486
20-Day Moving Average 4.9195
10-Day Moving Average 5.373
Average True Range 0.3098
ADX 29.11
+DI 25.6222
-DI 19.6849
Chandelier Exit (Long, 3 ATRs ) 4.9106
Chandelier Exit (Short, 3 ATRs ) 5.2194
Upper Bollinger Band 5.8913
Lower Bollinger Band 3.9477
Percent B (%b) 0.81
BandWidth 39.50808
MACD Line 0.0279
MACD Signal Line -0.1158
MACD Histogram 0.1437
Fundamentals Value
Market Cap 155.57 Million
Num Shares 28.1 Million
EPS -0.37
Price-to-Earnings (P/E) Ratio -14.95
Price-to-Sales 13.98
Price-to-Book 21.53
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.77
Resistance 3 (R3) 5.78 5.72 5.73
Resistance 2 (R2) 5.72 5.66 5.71 5.72
Resistance 1 (R1) 5.62 5.62 5.67 5.61 5.70
Pivot Point 5.56 5.56 5.58 5.55 5.56
Support 1 (S1) 5.46 5.50 5.51 5.45 5.36
Support 2 (S2) 5.40 5.46 5.39 5.34
Support 3 (S3) 5.30 5.40 5.33
Support 4 (S4) 5.29